Search

Displaying results 1801 - 1810 of 2482 in total
  1. Drug

    Orforglipron

    go.drugbank.com/drugs/DB18964
    ApprovedInvestigational

    Orforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. Developed to circumvent the adherence barriers and strict administration requirements of peptide-based GLP-1 therapies, its small-molecu...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  2. Drug

    Elzasonan

    go.drugbank.com/drugs/DB18969
    Investigational

    Elzasonan is under investigation in clinical trial NCT00275197 (A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  3. Drug

    Sevasemten

    go.drugbank.com/drugs/DB18983
    Investigational

    Sevasemten is under investigation in clinical trial NCT05291091 (Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  4. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    Baxdrostat is an orally bioavailable, highly selective, first-in-class small-molecule aldosterone synthase inhibitor (ASI) designed to block the production of aldosterone . It targets aldosterone excess, a primary underlying driver of tr...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  5. Drug

    OSU-6162

    go.drugbank.com/drugs/DB19178
    Investigational

    OSU-6162 is under investigation in clinical trial NCT05641623 (OSU6162 as Add-on in Ssri/snri-resistant Depression).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  6. Drug

    Methylone

    go.drugbank.com/drugs/DB19192
    Investigational

    Methylone is under investigation in clinical trial NCT05741710 (A Study to Assess the use of Methylone in the Treatment of PTSD).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  7. Drug

    Sofpironium

    go.drugbank.com/drugs/DB19325
    Approved

    Sofpironium is a "soft" anticholinergic analog of glycopyrronium that has been modified with a readily hydrolyzable ester moiety. Soft drugs are designed to reduce systemic toxicity while enhancing local efficacy by employing retrometabo...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  8. Drug

    Lanepitant

    go.drugbank.com/drugs/DB19599
    Experimental

    The usage of the INN stem '-pitant' in the name indicates that Lanepitant is a neurokinin NK1​ (substance P) receptor antagonist. Lanepitant has a monoisotopic molecular weight of 559.35 Da.

  9. Drug

    Fosfluconazole

    go.drugbank.com/drugs/DB19833
    Experimental

    Fosfluconazole is a small molecule drug. Fosfluconazole has a monoisotopic molecular weight of 386.07 Da.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  10. Drug

    TAK-243

    go.drugbank.com/drugs/DB15013
    Investigational

    TAK-243 is under investigation in clinical trial NCT03816319 (TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia).

    Categories: P-glycoprotein substrates